Overview

The Effect of Addition of Metformin to SGLT2 In Diabetic Patients With Heart Failure With Preserved Ejection Fraction

Status:
Not yet recruiting

Trial end date:
2024-12-01

Target enrollment:

Participant gender:

Summary

a prospective open-label, randomized controlled study to evaluate the efficacy of the addition of metformin to SGLT2 in diabetic patient with preserved ejection fraction

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

October University for Modern Sciences and Arts

Collaborator:

clinical research unit, El-sheikh zayed specialized hospital - Egyptian Ministry of health

Treatments:

Metformin